Table 1 Patient characteristics
From: Sequencing and curation strategies for identifying candidate glioblastoma treatments
|  | n = 30 |
|---|---|
Age, median (range) | 63 (25–81) |
Female, no. (%) | 12 (40%) |
Resections, no. (%) | |
 Initial | 19 (63%) |
 Biopsy only | 2 (7%) |
 Re-resection | 7 (23%) |
 Re-resection of subtotal | 2 (7%) |
Prior treatment of 7 recurrent tumors, no. | |
 RT/TMZ | 6 |
 Bevacizumab | 3 |
 Cetuximab | 2 |
 RT/Nivolimab | 1 |
 RT/Rindopepimut | 1 |
 CCNU | 1 |
 Gamma knife | 1 |
 Prior cranial RT, unrelated to GBM | 1 |
Days from initial resection to sample submission, median (IQR) | 67 (266) |
Sample preservation, no. (%) | n = 33 |
 Fresh frozen | 13 (40%) |
 OCT embedded | 12 (36%) |
 Formalin-fixed paraffin-embedded | 8 (24%) |
Tumor biomarkers, no./no. assessed | |
 EGFR amplification | 8/20 |
 MGMT methylation | 12/30 |
 IDH1 R132H mutation | 2/30 |